2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: Cambridge

Poster-Quality of Life and Outcomes

October 25, 2021

Characterizing Activities of Daily Living in MS Patients with Processing Speed Scores Above and below a Threshold Previously Shown to Predict Employment Status

Background: Cognitive impairment can occur early in the course of multiple sclerosis (MS) and worsen progressively over time, impacting...

Read More →

Poster-Non-imaging Biomarkers

October 25, 2021

Combinatorial Analysis of Plasma and DNA Methylation Biomarkers in African American Patients with Multiple Sclerosis

Background: African American patients are at increased risk of developing severe forms of multiple sclerosis and have been underrepresented...

Read More →

Poster-Methods of Care

October 25, 2021

Impact of the COVID-19 Pandemic on People with Multiple Sclerosis: Results from an International Survey

Background: The broad impact of the COVID-19 pandemic on people with multiple sclerosis (PwMS) and their health, behaviors, and ability to...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety and Effectiveness of Peginterferon Beta-1a in a Subgroup of African American Patients: Plegridy Observational Program Interim Analysis

Background: Limited data on baseline (BL) characteristics and disease severity exist for Black/African American (AA) patients with multiple...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Incidence and Severity of Natalizumab Infusion-Related Reactions during Infusion and Postinfusion Observation

Background: Natalizumab, an efficacious treatment for relapsing forms of multiple sclerosis, has an approved dosing of 300 mg infused...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a

Background: Although socioeconomic disparities that lead to differences in multiple sclerosis (MS) outcomes have been identified, specific...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Adherence and Persistence to Injectable Disease-Modifying Therapies Among Patients with Multiple Sclerosis Enrolled in US Commercial Plans

Background: In patients with multiple sclerosis (MS), adherence and persistence to disease-modifying therapies (DMTs) are important to...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Treatment Persistence, Safety, Tolerability, and Effectiveness of Diroximel Fumarate in the Real-World: Design of the Phase 4 Experience–US Study

Background: Diroximel fumarate (DRF) is an oral fumarate approved in the United States (US) for relapsing multiple sclerosis (MS). DRF...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

COVID-19 Prevention Behaviors and PCR Testing Among MS Patients Treated with Different Dmts: Survey Data from MS Paths

Background: Emerging data from people with multiple sclerosis (PwMS) suggest that some disease-modifying therapies (DMTs) may impact the...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem

Background: Dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefit–risk profile in patients with relapsing-remitting...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC